Trevi Therapeutics reports $107.6M cash; Phase 2a RIVER completed enrollment; CORAL 80% enrolled

Trevi Therapeutics, Inc.

Cash, cash equivalents, and marketable securities estimated at $107.6M as of Dec 31, 2024; runway into H2 2026.
Last patient completed final visit in Phase 2a RIVER trial (RCC); topline results expected Q1 2025.
Phase 2b CORAL trial (IPF chronic cough) now ~80% enrolled after positive SSRE; topline expected H1 2025.
SSRE analysis in Dec 2024 reaffirmed original sample size of N=160 for CORAL trial.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.